Rapid determination of p-aminohippuric acid in serum and urine by high-performance liquid chromatography

Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients

“…Inulin concentrations of the plasma and infusion samples were determined by use of an enzymatic assay based on the method of Kuehnle et al 34 The limit of quantification was 5 μg/mL (between‐run coefficients of variation <9.2%). PAH concentrations were determined by use of an HPLC assay with ultraviolet detection that was adapted from the method of Marsilio et al 35 The limit of quantification was 1.2 μg/mL (between‐run coefficients of variation <16.0%).…”

Determination of para-aminohippuric acid (PAH) in human plasma and urine by liquid chromatography–tandem mass spectrometry

“…A commonly used marker for estimating RPF is paraaminohippuric acid (PAH), since it is freely filtered at the glomerulus and undergoes extensive secretion and negligible reabsorption within renal tubules when its plasma concentration is low [1]. Analytical methods have been developed to measure PAH in human plasma and urine, such as liquid chromatography with electrochemical detection (LCEC) [2] and high-performance liquid chromatography with UV detection (HPLC-UV) [3][4][5][6][7][8][9][10]. In recent years, liquid chromatography coupled to electrospray ionisation tandem mass spectrometry (HPLC-ESI-MS/MS) has increasingly been used as a tool for drug assays in biological fluids due to the higher sensitivity and specificity of MS detection [11].…”

Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome

“…The concentrations were calculated by interpolation from a calibration curve, with a lower limit of quantification of 5 g/mL. The plasma concentrations of PAH were determined with a high-performance liquid chromatography method with ultraviolet detection adapted from Marsilio et al 27 The plasma concentrations of ET-1 were determined with a commercially available luminescent immunoassay kit (QET00 Quanti-Glo, R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany). PRA was determined by the measurement of angiotensin I with a high-performance liquid chromatography/tandem mass spectrometry method based on the work of Fredline et al 28 Plasma NE was determined with a commercial enzyme-linked immunosorbent assay kit (catalog no.…”